8-K: XOMA Royalty Corp Reports Strong Q2 2024 Results Driven by Milestone Achievements and Strategic Acquisitions

XOMA Royalty Corporation announced a profitable second quarter of 2024, driven by key milestones, strategic acquisitions, and increased royalty income.

Summary

• XOMA Royalty Corporation reported a net income of $16.0 million for the second quarter of 2024, a significant turnaround from a net loss of $5.4 million in the same period last year.
• Total income and revenues for the quarter reached $11.1 million, including $4.9 million from commercial products, $0.5 million from the OJEMDA milestone, and $5.0 million from a Rezolute milestone.
• The company completed the acquisition of Kinnate Pharmaceuticals, adding potential royalty streams and over $9.5 million in cash.
• Cash receipts for the quarter totaled $22.6 million, while $22.0 million was deployed to acquire new royalty and milestone interests.
• XOMA Royalty recorded a $19.3 million gain on the Kinnate acquisition due to the fair value of net assets exceeding the purchase price.
• A one-time, non-cash impairment charge of $9.0 million was recorded related to partnered programs with Aronora.
• The company's cash and cash equivalents stood at $149.9 million as of June 30, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company's strong financial performance, strategic acquisitions, and milestone achievements. The significant increase in net income and revenue, along with the successful acquisition of Kinnate, contribute to a favorable outlook. However, the non-cash impairment charge and increased expenses temper the sentiment slightly.

Positives

• The company achieved a significant increase in net income, turning a loss into a substantial profit.
• Revenue increased significantly year-over-year, driven by milestone payments and commercial product sales.
• The acquisition of Kinnate Pharmaceuticals added valuable assets and cash to the company's balance sheet.
• The company successfully expanded its portfolio with the addition of three commercial or late-stage programs from Dar Bioscience.
• XOMA Royalty has a strong cash position of $149.9 million, providing a solid foundation for future growth.
• The FDA approval of Day One's OJEMDA and the associated milestone payment and sales income are positive developments.
• The company is actively deploying capital to acquire new royalty and milestone interests.

Negatives

• A one-time, non-cash impairment charge of $9.0 million was recorded related to partnered programs with Aronora.
• General and administrative expenses increased significantly due to the Kinnate acquisition, including severance and consulting fees.
• Research and development expenses increased due to the ongoing clinical activities related to Kinnate's Phase 1 clinical trial.
• Net cash used in operating activities during the quarter was $2.2 million.

Risks

• The company's performance is dependent on the success of its partners' drug development programs and regulatory approvals.
• There is a risk that the therapeutic product candidates to which XOMA has a royalty interest may not receive regulatory approval.
• The company's licensees may require substantial funds to continue development, which may not be available.
• There is no guarantee that there will be a viable market for the products in which XOMA has an ownership or royalty interest.
• The company's future performance is subject to risks inherent in the biotechnology industry.

Future Outlook

The company anticipates potential commercial payments and regulatory approvals related to various assets in its portfolio, and expects its portfolio of partnered programs and licensed technologies to generate substantial milestone and royalty proceeds over time. XOMA Royalty plans to further solidify its foundation for future growth via a disciplined approach to capital deployment.

Management Comments

• The second quarter was marked by pipeline progress, the realization of several cash milestones, the addition of three commercial or late-stage programs, and the acquisition of Kinnate Pharmaceuticals, stated Owen Hughes, Chief Executive Officer of XOMA Royalty.
• Most important, children suffering from relapsed or refractory low-grade glioma (pLGG) have a new option with the approval of Day Ones OJEMDA, which is now our fifth commercial royalty.
• With a robust cash position in hand, we look to further solidify our foundation for future growth via a disciplined approach to capital deployment.

Industry Context

This announcement reflects the ongoing trend of biotech royalty aggregators acquiring and managing diverse portfolios of drug development assets. The company's focus on acquiring economic interests in both commercial and late-stage programs aligns with the industry's emphasis on de-risking drug development investments.

Comparison to Industry Standards

• XOMA's Q2 2024 performance, with a net income of $16.0 million, is a significant improvement compared to its own Q2 2023 loss of $5.4 million, indicating a strong turnaround.
• Compared to other royalty aggregators like Ligand Pharmaceuticals, which also focuses on acquiring royalty streams, XOMA's strategic acquisitions and milestone achievements in Q2 2024 demonstrate a proactive approach to portfolio growth.
• The $19.3 million gain on the Kinnate acquisition is a notable positive, suggesting effective deal structuring and value creation, which is a key metric for royalty aggregators.
• The $22.6 million in cash receipts from royalty and milestone payments highlights the company's ability to monetize its portfolio, a critical factor for long-term sustainability and growth in the royalty aggregation space.
• While companies like Royalty Pharma also operate in the royalty space, XOMA's focus on earlier-stage assets and strategic acquisitions differentiates its approach, potentially offering higher growth potential but also higher risk.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and strategic growth initiatives.
• Employees may experience increased job security and potential growth opportunities due to the company's expansion.
• Customers of XOMA's partners may benefit from the development and commercialization of new therapeutic products.
• Suppliers and creditors may see increased business opportunities due to the company's growth and financial stability.

Next Steps

• The company anticipates the FDA PDUFA action date for arimoclomol NDA on September 21, 2024.
• Takeda plans to initiate a global Phase 3 trial of mezagitamab in ITP in the second half of fiscal year 2024.
• XOMA Royalty will continue to deploy capital to acquire new royalty and milestone economic interests.
• The company will continue to monitor the progress of its partnered programs and licensed technologies.

Key Dates

Keywords

royalty, biotechnology, milestone, acquisition, pharmaceutical, drug development, FDA approval, commercialization, clinical trials, portfolio